Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α‐2b and ribavirin

Gallegos‐Orozco, Juan F.; Castillo, A. Loaeza-del; Fuentes, Ana; García-Sandoval, M.; Soto, Luis; Rodríguez, R.; Gutiérrez‐Ruiz, María Concepción; Gutiérrez-Reyes, Gabriela; Bonder, Alan; Olivera, Marco

doi:10.1111/j.1478-3231.2005.1040.x

Cited by 8 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction of serum HCV RNA levels seems greater than that reported by Spanish and German studies, but is similar to the report from Mexico [12,29,30] . These findings implicated that Taiwanese patients probably have better EVR than Western patients, especially at the first phase.…”

Section: Discussioncontrasting

confidence: 44%

Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan

Hsu

Liu²,

Lai³

et al. 2007

Intervirology

View full text Add to dashboard Cite

Objectives: Early hepatitis C viral (HCV) kinetics following pegylated interferon-α (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-α dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters Ε (effectiveness at inhibiting viral production)and δ (loss rate of infected cells) were estimated from viral loads and alanine aminotransferase (ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The Ε ranged from 0.4128 to 0.9904 and δ from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing.

show abstract

Section: Discussioncontrasting

confidence: 44%

Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan

Hsu

Liu²,

Lai³

et al. 2007

Intervirology

View full text Add to dashboard Cite

show abstract

“…Rapid and early virological responses, defined as a drop of HCV RNA below detection limit at treatment week 4 and as a drop in viremia level to undetectable values or by more than or equal to 2 log at treatment week 12, are important predictors of SVR in chronic HCV infection in the nontransplant setting (24,28,29). In our series, 92% of patients with HCV RNA below detection limit at week 12, but only 14% of those with positive HCV RNA at week 12, reached an SVR.…”

Section: Discussionmentioning

confidence: 99%

Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In general, we follow the evolving treatment guidelines for CHC as recommended by various authoritative groups [4,5], including making decisions about how long treatment should be continued based on initial reductions in HCV-RNA and how well therapy is being tolerated at the end of 3 months in compliant patients [32,33]. Each patient was asked to consider their treatment options, including expectant management.…”

Section: Design and Collection Of Datamentioning

confidence: 99%

Reasons Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer Treatment: Do They Alter Their Decision with Time?

Khokhar

Lewis

2007

Dig Dis Sci

View full text Add to dashboard Cite

This study was designed to determine the percentage of treatment-naïve patients infected with chronic hepatitis C virus who make an informed choice to forego (defer) treatment with pegylated interferon regimens in the absence of any medical, psychosocial, or other contraindications, and to reassess their decision by using a questionnaire at least 1 year later. Patient charts dating from 2001 were retrieved and retrospectively analyzed for the following data: patient age, gender, race, hepatitis C viral load, genotype, liver biopsy results, hepatic imaging results, peak alanine aminotransferase (ALT) levels, comorbid conditions, source of infection, estimated duration of infection, and reasons given by the patient for declining pegylated interferon-based treatment at the time of their consultation. A questionnaire survey sought to determine their satisfaction with their initial decision. Of 446 patient charts reviewed, 280 patients were treatment-naïve and were judged to have no contraindications to receiving interferon-based therapy. Of these, 115 (41%) opted to defer treatment and are the subject of this analysis. Women declining therapy outnumbered men by approximately 3 to 2. Middle-aged patients (45-55 years) were most likely to choose expectant therapy compared with older or younger individuals. The proportion of African American patients who deferred therapy (48%) was higher than non-African American patients (36.6%). More than 90% of the patients choosing to be followed were genotype 1. Peak ALT values were normal in 37% and<2X upper limits of normal (ULN) in another 40%. The estimated duration of chronic hepatitis C infection was >16 years in approximately three-quarters of individuals. The most common source of their infection was intravenous drug use followed by transfusion-related. The most common reason for opting not to receive treatment, given by nearly two-thirds of patients, was the asymptomatic nature of their infection coupled with their concern about side effects of the medications. Approximately 10% had unfavorable social situations, including a lack of support or health insurance, that precluded receiving therapy (despite the availability of indigent care programs offered by the pharmaceutical manufacturers). Only five patients (4.3%) cited doubts about efficacy as the main reason that they did not want to be treated. The questionnaire survey at 1 year found that 79% of the patients confirmed their ongoing satisfaction with their initial decision to decline treatment, and another 10.6% indicated that they were still "moderately satisfied" with their decision and unlikely to change it in the near-future. Only six patients (7%) voiced their current dissatisfaction with expectant management and expressed the desire to have a follow-up discussion about treatment options. Of the remaining three patients (3.5%), two had already started treatment and one was deceased (of non-liver-related causes). A significant proportion of patients infected with hepatitis C virus who are otherwise eligible for the...

show abstract

Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α‐2b and ribavirin

Abstract: Our data indicate that peginterferon alpha-2b plus ribavirin treatment produces significant changes in HCV dynamics that can be detected as early as 48 h after the first dose of peginterferon alpha-2b and that these changes are useful in predicting response to therapy in CHC patients.

Cited by 8 publications

References 20 publications

Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan

Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan

Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome

Reasons Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer Treatment: Do They Alter Their Decision with Time?

Contact Info

Product

Resources

About